Tarcisio Passos Ribeiro de Campos1, Luciana Batista Nogueira2, Bruno Trindade3, Ethel Mizrahy Cuperschmid4. 1. NRI - Nucleo de Radiações Ionizantes, Professor do Departamento de Engenharia Nuclear da Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. 2. Departamento de Anatomia e Imagem, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. 3. Programa de Ciências e Técnicas Nucleares, Núcleo de Radiações Ionizantes - NRI (Grupo de Pesquisa), UFMG, Brazil. 4. Centro de Memória da Medicina, Faculdade de Medicina, Universidade Federal de Minas Gerais, Brazil.
Abstract
AIM: To provide a comparative dosimetric analysis of permanent implants of Ho(166)-seeds and temporary HDR Ir(192)-brachytherapy through computational simulation. BACKGROUND: Brachytherapy with Ir(192)-HDR or LDR based on temporary wires or permanent radioactive seed implants can be used as dose reinforcement for breast radiation therapy. Permanent breast implants have not been a practical clinical routine; although, I(125) and Pd(103)-seeds have already been reported. Biodegradable Ho(166)-ceramic-seeds have been addressed recently. MATERIAL AND METHODS: Simulations of implants of nine Ho(166)-seeds and equivalent with HDR Ir(192)-brachytherapy were elaborated in MCNP5, shaped in a computational multivoxel simulator which reproduced a female thorax phantom. Spatial dose rate distributions and dose-volume histograms were generated. Protocol's analysis involving exposure time, seed's activities and dose were performed. RESULTS: Permanent Ho(166)-seed implants presented a maximum dose rate per unit of contained activity (MDR) of 1.1601 μGy h(-1) Bq(-1); and, a normalized MDR in standard points (8 mm, equidistant to 03-seeds - SP1, 10 mm - SP2) of 1.0% (SP1) and 0.5% (SP2), respectively. Ir(192)-brachytherapy presented MDR of 4.3945 × 10(-3) μGy h(-1) Bq(-1); and, 30% (SP1), and 20% (SP2). Therefore, seed's implant activities of 333 MBq (Ho(166)) and 259 GBq (Ir(192)) produced prescribed doses of 58 Gy (SP1; 5d) and 56 Gy (SP1, 5 fractions, 6 min), respectively. CONCLUSIONS: Breast Ho(166)-implants of 37-111 MBq are attractive due to the high dose rate near 6-10 mm from seeds, equivalent to Ir(192)-brachytherapy of 259 GBq (3 fractions, 6 min) providing similar dose in standard points at a week; however, with spatial dose distribution better confined. The seed positioning can be adjusted for controlling the breast tumor, in stages I and II, in flat and deep tumors, without any breast volumetric limitation.
AIM: To provide a comparative dosimetric analysis of permanent implants of Ho(166)-seeds and temporary HDR Ir(192)-brachytherapy through computational simulation. BACKGROUND: Brachytherapy with Ir(192)-HDR or LDR based on temporary wires or permanent radioactive seed implants can be used as dose reinforcement for breast radiation therapy. Permanent breast implants have not been a practical clinical routine; although, I(125) and Pd(103)-seeds have already been reported. Biodegradable Ho(166)-ceramic-seeds have been addressed recently. MATERIAL AND METHODS: Simulations of implants of nine Ho(166)-seeds and equivalent with HDR Ir(192)-brachytherapy were elaborated in MCNP5, shaped in a computational multivoxel simulator which reproduced a female thorax phantom. Spatial dose rate distributions and dose-volume histograms were generated. Protocol's analysis involving exposure time, seed's activities and dose were performed. RESULTS: Permanent Ho(166)-seed implants presented a maximum dose rate per unit of contained activity (MDR) of 1.1601 μGy h(-1) Bq(-1); and, a normalized MDR in standard points (8 mm, equidistant to 03-seeds - SP1, 10 mm - SP2) of 1.0% (SP1) and 0.5% (SP2), respectively. Ir(192)-brachytherapy presented MDR of 4.3945 × 10(-3) μGy h(-1) Bq(-1); and, 30% (SP1), and 20% (SP2). Therefore, seed's implant activities of 333 MBq (Ho(166)) and 259 GBq (Ir(192)) produced prescribed doses of 58 Gy (SP1; 5d) and 56 Gy (SP1, 5 fractions, 6 min), respectively. CONCLUSIONS: Breast Ho(166)-implants of 37-111 MBq are attractive due to the high dose rate near 6-10 mm from seeds, equivalent to Ir(192)-brachytherapy of 259 GBq (3 fractions, 6 min) providing similar dose in standard points at a week; however, with spatial dose distribution better confined. The seed positioning can be adjusted for controlling the breast tumor, in stages I and II, in flat and deep tumors, without any breast volumetric limitation.
Entities:
Keywords:
Breast brachytherapy; HDR Ir-192; Ho-166 seeds; MCNP; Permanent implants
Authors: Mark J Rivard; Bert M Coursey; Larry A DeWerd; William F Hanson; M Saiful Huq; Geoffrey S Ibbott; Michael G Mitch; Ravinder Nath; Jeffrey F Williamson Journal: Med Phys Date: 2004-03 Impact factor: 4.071
Authors: James W Jakub; Richard J Gray; Amy C Degnim; Judy C Boughey; Mary Gardner; Charles E Cox Journal: Am J Surg Date: 2009-12-02 Impact factor: 2.565
Authors: Eric C Ko; Christopher D Koprowski; Diana Dickson-Witmer; Emily Penman; Michael Sorensen; Alexandra L Hanlon; Sarah Sammons; Andrew Farach; Jon Strasser Journal: Brachytherapy Date: 2010-02-13 Impact factor: 2.362
Authors: Grace L Smith; Jing Jiang; Thomas A Buchholz; Ying Xu; Karen E Hoffman; Sharon H Giordano; Kelly K Hunt; Benjamin D Smith Journal: Int J Radiat Oncol Biol Phys Date: 2013-11-21 Impact factor: 7.038
Authors: C A Perez; M E Taylor; K Halverson; D Garcia; R R Kuske; M A Lockett Journal: Int J Radiat Oncol Biol Phys Date: 1996-03-15 Impact factor: 7.038